Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states.
Intravenous immunoglobulin can be a very effective form of treatment for patients with primary immunodeficiency states. Recommendations for intravenous dosing previously have been empirically derived. In order to determine the potential prolongation of intervals between infusions following the administration of 500 mg/kg of intravenous immunoglobulin, 11 patients were studied. This high-dose therapy was well tolerated and resulted in a modest prolongation of therapeutic IgG levels when compared with lower-dose 150 mg/kg regimens. Significant variability among individual patients was observed. Implications of this high-dose therapy are discussed.
D000328:Adult; D000361:Agammaglobulinemia / Q000276:immunology / Q000628:therapy*; D000368:Aged; D002648:Child; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D016756:Immunoglobulins, Intravenous; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous